Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

First vaccines targeting 'cruise ship virus' sail into clinical trials

Nature Medicine volume 19, pages 1076–1077 (2013)Cite this article

Subjects

A few months ago, Charles Arntzen dined on a plate of buttery mussels. That night, he fell ill with what he believes was norovirus, a nasty bug known for causing profuse vomiting and diarrhea. It was a cruel twist of fate for someone who studies the virus at the Center for Infectious Diseases and Vaccinology at Arizona State University in Tempe. Knowing all too well that no specific medicine exists to treat norovirus illness (or even to prevent the problem), Arntzen buckled down in the bathroom and spent the better part of four days “getting rid of everything,” as he puts it. “I was so miserable I couldn't do a thing.”

Arntzen hopes that soon others won't have to endure the same experience. He and many other researchers are now working to develop a vaccine against the highly contagious, vomit-inducing virus, with the lead candidate already tested in humans and at least two more contenders slated to enter clinical trials in the next couple of years. And on the therapeutics front, researchers from the US National Institute of Allergy and Infectious Diseases (NIAID) reported in the September issue of the Journal of Virology that they had produced the first monoclonal antibodies proven to neutralize human norovirus and block infection in chimpanzees1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chen, Z. et al. J. Virol. 87, 9547–9557 (2013).

    Article  CAS  Google Scholar 

  2. Hall, A.J. et al. Emerg. Infect. Dis. 19, 1198–1205 (2013).

    Article  Google Scholar 

  3. Payne, D.C. et al. N. Engl. J. Med. 368, 1121–1130 (2013).

    Article  CAS  Google Scholar 

  4. Hall, A.J., Curns, A.T., McDonald, L.C., Parashar, U.D. & Lopman, B.A. Clin. Infect. Dis. 55, 216–223 (2012).

    Article  Google Scholar 

  5. Bartsch, S.M., Lopman, B.A., Hall, A.J., Parashar, U.D. & Lee, B.Y. Vaccine 30, 7097–7104 (2012).

    Article  Google Scholar 

  6. Simmons, K., Gambhir, M., Leon, J. & Lopman, B. Emerg. Infect. Dis. 19, 1260–1267 (2013).

    Article  Google Scholar 

  7. Atmar, R.L. et al. N. Engl. J. Med. 365, 2178–2187 (2011).

    Article  CAS  Google Scholar 

  8. Tamminen, K., Lappalainen, S., Huhti, L., Vesikari, T. & Blazevic, V. PLoS One 8, e70409 (2013).

    Article  CAS  Google Scholar 

  9. Fang, H., Tan, M., Xia, M., Wang, L. & Jiang, X. PLoS ONE 8, e63269 (2013).

    Article  CAS  Google Scholar 

Download references

Authors
  1. Cassandra Willyard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Willyard, C. First vaccines targeting 'cruise ship virus' sail into clinical trials. Nat Med 19, 1076–1077 (2013). https://doi.org/10.1038/nm0913-1076

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0913-1076

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology